Competition in full swing for the ₩100 bil Humira mkt
By Lee, Tak-Sun | translator Alice Kang
22.02.23 06:18:14
가나다라
0
Celltrion’s ‘Yuflyma’ reimbursed form March… the second biosimilar to be approved after Samsung-Yuhan’s ‘Adalloce’
Insurance price cap set at ₩244,877, same as Adalloce… Will Humira be able to defend the market with its 30% discounted price?
On how the market that was once dominated by its only biosimilar option, Samsung Bioepis’ Adalloce, will change with the entry of Celltrion in the market, remains the focus of attention. Humira, which is mainly used to treat rheumatoid arthritis, has formed a market worth ₩100 billion in Korea.
Celltrion’s Humira (Abbvie, adalimumab) biosimilar ‘Yuflyma pen injection 40mg/0.4mL)’ will be reimbursed from March 1st. Its insurance price cap was set at ₩244,877, identical to Samsung Bioepis’s ‘Adalloce.’
As the price ceiling for the original dru
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)